Who are Disitamab Vedotin combined with Tislelizumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/disitamab-vedotin-combined-with-tislelizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Disitamab Vedotin combined with Tislelizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Disitamab Vedotin combined with Tislelizumab (Disitamab Vedotin combined with Tislelizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibody-drug conjugate combined with PD-1 inhibitor. Area: Oncology.

marketed Antibody-drug conjugate combined with PD-1 inhibitor HER2 (disitamab vedotin); PD-1 (tislelizumab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Disitamab Vedotin combined with Tislelizumab (Disitamab Vedotin combined with Tislelizumab) — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Disitamab vedotin delivers a cytotoxic payload to HER2-expressing cancer cells while tislelizumab simultaneously blocks PD-1 to enhance anti-tumor immune response.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Disitamab Vedotin combined with Tislelizumab TARGET	Disitamab Vedotin combined with Tislelizumab	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	marketed	Antibody-drug conjugate combined with PD-1 inhibitor	HER2 (disitamab vedotin); PD-1 (tislelizumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibody-drug conjugate combined with PD-1 inhibitor class)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Disitamab Vedotin combined with Tislelizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/disitamab-vedotin-combined-with-tislelizumab. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab